193 related articles for article (PubMed ID: 20103680)
1. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma.
Schadler KL; Zweidler-McKay PA; Guan H; Kleinerman ES
Clin Cancer Res; 2010 Feb; 16(3):848-56. PubMed ID: 20103680
[TBL] [Abstract][Full Text] [Related]
2. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature.
Reddy K; Cao Y; Zhou Z; Yu L; Jia SF; Kleinerman ES
Angiogenesis; 2008; 11(3):257-67. PubMed ID: 18344025
[TBL] [Abstract][Full Text] [Related]
3. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas.
Yu L; Su B; Hollomon M; Deng Y; Facchinetti V; Kleinerman ES
Cancer Res; 2010 Feb; 70(4):1334-43. PubMed ID: 20124484
[TBL] [Abstract][Full Text] [Related]
4. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation.
Stewart KS; Zhou Z; Zweidler-McKay P; Kleinerman ES
Blood; 2011 Jan; 117(2):719-26. PubMed ID: 20944072
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.
Zhou Z; Stewart KS; Yu L; Kleinerman ES
Angiogenesis; 2011 May; 14(2):125-33. PubMed ID: 21184173
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels.
Reddy K; Zhou Z; Schadler K; Jia SF; Kleinerman ES
Mol Cancer Res; 2008 Jun; 6(6):929-36. PubMed ID: 18567797
[TBL] [Abstract][Full Text] [Related]
7. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.
Reddy K; Zhou Z; Jia SF; Lee TH; Morales-Arias J; Cao Y; Kleinerman ES
Int J Cancer; 2008 Aug; 123(4):831-7. PubMed ID: 18537159
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Zhou Z; Bolontrade MF; Reddy K; Duan X; Guan H; Yu L; Hicklin DJ; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(16):4867-73. PubMed ID: 17699866
[TBL] [Abstract][Full Text] [Related]
9. Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.
Hamdan R; Zhou Z; Kleinerman ES
Mol Cancer Ther; 2014 Feb; 13(2):483-91. PubMed ID: 24282276
[TBL] [Abstract][Full Text] [Related]
10. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature.
Lee TH; Bolontrade MF; Worth LL; Guan H; Ellis LM; Kleinerman ES
Int J Cancer; 2006 Aug; 119(4):839-46. PubMed ID: 16557578
[TBL] [Abstract][Full Text] [Related]
11. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo.
Bolontrade MF; Zhou RR; Kleinerman ES
Clin Cancer Res; 2002 Nov; 8(11):3622-7. PubMed ID: 12429654
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.
Real C; Remédio L; Caiado F; Igreja C; Borges C; Trindade A; Pinto-do-Ó P; Yagita H; Duarte A; Dias S
PLoS One; 2011 Apr; 6(4):e18323. PubMed ID: 21483741
[TBL] [Abstract][Full Text] [Related]
13. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
Zhou Z; Reddy K; Guan H; Kleinerman ES
Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
[TBL] [Abstract][Full Text] [Related]
14. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
15. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
Guan H; Zhou Z; Gallick GE; Jia SF; Morales J; Sood AK; Corey SJ; Kleinerman ES
Mol Cancer Ther; 2008 Jul; 7(7):1807-16. PubMed ID: 18644993
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
Chernoguz A; Crawford K; Donovan E; Vandersall A; Berglund C; Cripe TP; Frischer JS
J Surg Res; 2012 Mar; 173(1):1-9. PubMed ID: 21658718
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
18. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model.
Zhou Z; Zhou RR; Guan H; Bucana CD; Kleinerman ES
Mol Cancer Ther; 2003 Dec; 2(12):1313-9. PubMed ID: 14707272
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
20. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.
Guan H; Jia SF; Zhou Z; Stewart J; Kleinerman ES
Clin Cancer Res; 2005 Mar; 11(5):2008-17. PubMed ID: 15756027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
